











**Published Standard – No.1 – Applications (National)**

	<b>App Type</b>	<b>No. of Apps</b>	<b>Performance</b>	<b>Target Days</b>	<b>Average Days</b>
1	Complex timetable (National new MA applications) Complex new MA applications, e.g. novel therapies, new actives	0		210.0	-
2	Major timetable (National) New MRLs. All other MA applications (excl. MAPI and Copycats)	1		180.0	73.0
3	Standard timetable (National Type II variations. New MA - MAPIs and Copycats. New VHRs)	4		120.0	6.0
4	Shortened timetable (National Renewals (MA and VHR) Type IB variations. New ATC (type B). Out of Scope MRLs)	32		60.0	13
5	Minor timetable (National) Type IA variations. Administrative Type IB variations. New ATC (Type A/S). ATC variations and renewals.	47		30.0	6.0
6	Batch timetable (National) specific Batch Control.	6		20.0	0
7	Autogenous Vaccines. New & Variations	4		45.0	34

**Published Standard – No.1 – Applications (Other)**

	<b>App Type</b>	<b>No. of Apps</b>	<b>Performance</b>
8	Mock ups	164	 98.8%
9	Validation	271	 100%
10	Issue of authorised documentation	453	 100%

**Published Standard – No.1 – Applications (European)**

	<b>App Type</b>	<b>No. of Apps</b>	<b>Performance</b>
11	New Centralised (CAP)	4	100%
12	New Decentralised (DCP)	20	100%
13	New Mutual Recognition (MRP) and New DCP	17	100%
14	MRP Variations (Type IB & II) and Renewals	103	100%

**Published Standard – No. 2 – Public Assessment Reports**

	<b>App Type</b>	<b>Total No</b>	<b>Performance</b>
15	Publishing Summary of Product Characteristics (SPCs)	0	-
16	Publishing Public Assessment Reports (PuARs)	0	-
17	Updating PuARs	10	100%

**Published Standard – No. 3 – Quality of Documentation**

	<b>App Type</b>	<b>No of Apps</b>	<b>Performance</b>
18	Unreturned Documents	862	99.1%

**Published Standard – No. 4 – Import, Export and Batch Release Schemes**

	<b>App Type</b>	<b>No of Apps</b>	<b>Performance</b>	<b>Target Days</b>	<b>Average Days</b>
19	Applications for new products	61	100%	15	2.0
20	All other applications	116	100%		
	• Urgent	0		2	-
	• Non-Urgent	116		10	1.0
21	Export	127	100%	10	4.7
22	Batch Release	776	100%	10	4.3

**Published Standard – No. 5 – Pharmacovigilance**

	<b>Task</b>	<b>No.</b>	<b>Performance</b>
23	Human, Animal & Environmental AERs	<b>1873</b>	99.79%
24	PSURs	<b>380</b>	100%
25	Inspections	<b>6</b>	100%

**Published Standard – No. 6 – Inspections**

	<b>Task</b>	<b>No.</b>	<b>Performance</b>	<b>Target Days</b>	<b>Average Days</b>
26	Inspections within 3 years (GMP) or 5 years (GDP) of last inspection.	<b>23</b>	95.7%	-	-
	• GMP	14		-	-
	• GDP	9			
27	Final Inspection Reports	<b>23</b>	100%	90.0	13.0
28	Product defect reports	<b>16</b>	100%	-	-
	• High risk <5 days	1			
	• Low risk <10 days	15			

**Key:****Dark Green** - Excellent 100%**Light Green** - Excellent, but some targets missed**Amber** - Effective**Red** - Ineffective**Additional information about ‘ambers’ and ‘reds’**

The VMD continuously monitors all targets and puts in place countermeasures, where possible, to ensure targets are met.

However, sometimes a performance standard may fall into the effective or ineffective category and there are a number of reasons why this may happen, e.g. high volume of applications, staff resource, complexity of applications requiring additional input, etc